BioMarin Pharma (BMRN): Four Domain Field Data Stronger Than Previous Two Domain Data - Leerink

Leerink Partners analyst, Joseph Schwartz, reiterated his Outperform rating on share of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) after connecting with patient advocates and seeing additional clinical data including all four domains of the primary endpoint. The analyst believes that this appears stronger than the two-domain data presented previously.

The analyst stated "we are encouraged by growing awareness and improving diagnostic protocols for the disease, which could ultimately boost patient identification and long term Brineura sales. However, we noticed a lower propensity to treat patients in ex-US geographies". This led the analyst to temper his outlook for markets beyond the US borders.

No change to the price target of $127.

For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.

Shares of BioMarin Pharmaceutical Inc. closed at $91.67 yesterday.

You May Also Be Interested In

• UBS Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
• Citi Downgrades UBS AG (UBSG:SW) (UBS) to Neutral
• Fiserv (FI) PT Raised to $175 at TD Cowen